ResearchBrain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model
ResearchNeuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects
ResearchCorrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]
ResearchPharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
ResearchEffects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ(+) and Aβ(-) dementia with Lewy bodies patients
ResearchDiscordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake
ResearchPlasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease
ResearchKey considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation
ResearchPredicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency
ResearchResponse to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database
ResearchFeasibility of Identifying Acute Nontraumatic Intracerebral Hemorrhage Events Using Diagnostic Coding Among Veterans with Mild Cognitive Impairment or Alzheimer's Dementia
ResearchMultimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease
ResearchLong-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study